[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
January 1990

Down Syndrome and 3,3′,5′-Triiodothyronine

Author Affiliations

Centre de Recherches Génétique Humaine et Maladies de l'Intelligence Institut de Progenèse 45, rue des Saints-Pères 75270 Paris cedex 06 France
Service Central des radio-isotopes Hôpital des Enfants Malades 149, rue de Sèvres 75743 Paris cedex 15 France

Am J Dis Child. 1990;144(1):19. doi:10.1001/archpedi.1990.02150250021017

Sir.—Since publications cross geographic but only rarely linguistic boundaries, we wish to bring to your attention our recent publication on elevated thyrotropin (TSH) levels and Down syndrome (DS).1

Our findings are in accordance with those observed by Sharav et al.2

A prospective survey was carried out on 78 patients with DS (age range, 6 months to 16 years; mean, 9.08±6.99 years) followed up at our genetics clinic, Hopital des Enfants Malades, Paris, France. The TSH levels were significantly elevated (t = 9.5; P<<<.001) in the group with trisomy 21 (3.99±2.54 mU/L) as compared with 214 age-matched normal children (2.01±0.85 mU/L). There was no difference in free thyroxine (T4) levels between both groups (trisomy 21, 20.55±3.81 pmol/L; controls, 21.12±3.19 pmol/L). Free triiodothyronine (T3) levels, however, tended to be lower in the DS group (7.09±1.68 pmol/L) vs controls (7.92±1.39 pmol/L) (t=2.4; P=.05).

We observed a

First Page Preview View Large
First page PDF preview
First page PDF preview